U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Regulatory Information
  3. Search for FDA Guidance Documents
  4. Medical Devices and Clinical Trial Design for the Treatment or Improvement in the Appearance of Fungally-Infected Nails
  1. Search for FDA Guidance Documents

GUIDANCE DOCUMENT

Medical Devices and Clinical Trial Design for the Treatment or Improvement in the Appearance of Fungally-Infected Nails Guidance for Industry and Food and Drug Administration Staff March 2016

Download the Final Guidance Document
Final
Docket Number:
FDA-2014-D-1849
Issued by:
Guidance Issuing Office
Center for Devices and Radiological Health

A variety of diseases can affect the appearance of nails, including fungal infection. This guidance is intended to provide recommendations regarding clinical trial design for medical devices intended either (1) to provide improvement in the appearance of nails affected by onychomycosis, that is, to affect the structure/function of the nails or (2) to treat onychomycosis (fungal nail infection). All marketed devices to date have been 510(k)-cleared for visual improvement, with Indication for Use statements such as “temporary increase of clear nail in patients with onychomycosis (e.g., dermatophytes Trichophyton rubrum and Trichophyton mentagrophytes, and/or yeasts Candida albicans).” Some elements of this guidance will be primarily applicable to non-ablative energy-based devices, although the basic principles may be broadly applicable to all devices.

Submit Comments

Submit Comments Online

You can submit online or written comments on any guidance at any time (see 21 CFR 10.115(g)(5))

If unable to submit comments online, please mail written comments to:

Dockets Management
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852

All written comments should be identified with this document's docket number: FDA-2014-D-1849.

Back to Top